The scholarly study, published in the October edition of the journal Neurotherapeutics, found that the medication, AT2101, which has been studied for Gaucher disease also, improved electric motor function, stopped irritation in the mind and reduced levels of alpha-synuclein, a proteins critically involved with Parkinson's. Although the precise reason behind Parkinson's is unknown, evidence points to an accumulation of alpha-synuclein, which has been found to be common to all social people with the disorder. The protein is thought to damage the neurons in the brain that make dopamine, a neurotransmitter that helps regulate a number of functions, including coordination and movement.The outcomes of the international, multi-center, single-arm clinical trial executed at sixteen centers in U.S., Canada, UK and Belgium, were published today in the August problem of the peer-examined Journal of Urology, the state journal of the American Urological Association. This data confirms the outcomes of earlier studies from independent doctors pointing to a high amount of efficacy and individual satisfaction. ‘This research demonstrated that the MiniArc method is quick, carries minimal affected person morbidity and is quite tolerable, highlighted by brief facility remains, minimal post-op distress and a quick go back to normal activities,’ stated Dr.